Posted on 01.03.2012 in JAK2 inhibitors, Research
The New England Journal of Medicine – 1 March 2012
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Abstract from the journal regarding the study undertaken by leading MPD physicians into the treatment options for myelofibrosis, evaluating the efficacy and safety of Ruxolitinib compared with the best available therapy, in patients with myelofibrosis.
Read more ……
Posted on 17.11.2011 in JAK2 inhibitors, Research
Incyte have announced that the FDA (U.S. Food and Drug Administration) have granted marketing approval for 
Jakafi™ (ruxolitinib) for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythaemia vera MF and post-essential thrombocythaemia MF. Patients with intermediate and high-risk MF represent 80 to 90 percent of MF patients. Jakafi (JAK-ah-fye) is the first and only product to be approved by the FDA for MF, and the first in a new class of drugs, known as JAK inhibitors, to be approved for any indication. Jakafi is an oral JAK1 and JAK2 inhibitor.
You can read the full press release here.
Incyte is a Wilmington, Delaware-based drug discovery and development company focused on developing proprietary, orally available drugs for serious unmet medical needs in oncology and inflammation. For more information visit the Incyte website.
Posted on 31.03.2011 in JAK2 inhibitors, Research
The company Incyte, working under a strategic alliance with Novartis, has several new drugs currently under trial for the treatment of myelofibrosis. Novartis has issued a press release describing how the trial is going. The data from the Comfort II study shows that people being treated with the JAK2 inhibitor drug INC424 under trial are showing “marked clinical improvement”. Their spleen size after 48 weeks of treatment was reduced, compared with the best available therapy currently being used to treat their illness.
